证券代码：002891 证券简称：中宠股份 编号：2022-006 烟台中宠食品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------------|------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 北京才誉资产管理企业 | ( 有限合伙 ) 贾巍 | | | 北京城天九投资有限公司 | 张吉喆 | | | 北京颐和久富投资管理有限公司 | 陈帅 | | | 工银瑞信基金管理有限公司 | 袁辰昱 | | | 工银瑞信基金管理有限公司 | 齐欢 | | 活动参与人员 | 共青城寻阑私募基金管理有限公司 | 钟杵 | | | 国金证券股份有限公司 | 尹新悦 | | | 国金证券股份有限公司 | 谢丽媛 | | | 建信基金管理有限责任公 ...

证券代码：002891 证券简称：中宠股份 编号：2022-007 烟台中宠食品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------------------------------|----------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 安信证券股份有限公司 | 王朔 | | | 安信证券股份有限公司 | 夏心怡 | | 活动参与人员 | 国联证券股份有限公司 | 广州云禧私募证券投资基金管理有限公司 龙华明 陈安宇 | | | 中国银河证券股份有限公司 | 谢芝优 | | 时间 地点 | 2022 年 9 月 22 日 烟台中宠食品股份有限公司 | | | 上市公司接待人 | 董事会秘书：任福照 ...

编号：2022-008 证券代码：002891 证券简称：中宠股份 烟台中宠食品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------------------------------|--------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系 | □媒体采访 | 业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | Teng Yue Partners, L.P. | 葛文扬 | | | | Willing Capital Management Limited 王波锦 | | | 博道基金管理有限公司 | 孙文龙 | | | 东亚前海证券有限责任公司 | 赵雅斐 | | | 广东睿璞投资管理有限公司 国泰君安证券股份有限公司 | 田振刚 王海军 | | | 国投瑞银基金管理有限公司 | 冯新月 | | | 国投瑞银基金 ...

证券代码：002891 证券简称：中宠股份 编号：2022-005 烟台中宠食品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------------------------------------------|--------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | Miura Global Management | ， LLC 范丽娜 | | | 财通证券股份有限公司 东方证券股份有限公司 华安证券股份有限公司 | 王宇璇 肖嘉颖 刘京松 | | | 华西证券股份有限公司 | 卢周伟 | | | 华夏基金管理有限公司 金鹰基金管理有限公司 | 谢子情 李敏晗 | | 活动参与人员 | 开源证券股份有限公司 | 陈雪丽 | | ...

Financial Performance - The company's revenue for Q3 2022 reached ¥852,684,008.64, representing a year-over-year increase of 12.98%[7] - Net profit attributable to shareholders for the same period was ¥46,282,289.83, up 49.19% compared to the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥47,037,216.46, reflecting a 49.93% increase year-over-year[7] - The basic earnings per share for Q3 2022 was ¥0.1574, a 49.19% increase from the same period last year[7] - Net profit attributable to the parent company increased to ¥576,713,078.22, up from ¥473,643,423.00, representing a growth of 21.8%[36] - Net profit for the current period reached CNY 126,626,958.93, an increase of 19.6% compared to CNY 105,848,626.40 in the previous period[40] - Operating profit increased to CNY 165,097,592.88, up from CNY 127,943,776.47, reflecting a growth of 29.0%[40] - Total comprehensive income for the current period was CNY 126,852,958.94, compared to CNY 100,995,313.96 in the previous period, reflecting an increase of 25.7%[40] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,294,992,425.52, which is a 9.28% increase from the end of the previous year[7] - The company's equity attributable to shareholders increased to ¥1,908,488,156.46, marking a 4.93% rise compared to the previous year[7] - Total assets increased to ¥3,294,992,425.52 from ¥3,015,181,615.47, marking a growth of 9.3%[36] - Total liabilities rose to ¥1,232,482,200.46, compared to ¥1,069,380,292.64, an increase of 15.3%[36] - The total equity attributable to shareholders reached ¥1,908,488,156.46, up from ¥1,818,877,375.13, indicating a growth of 4.9%[36] Cash Flow - The cash flow from operating activities showed a significant decline, with a net amount of ¥33,666,990.04, down 65.38% year-over-year[7] - Cash received from other operating activities decreased by 64.46% to 1,425.07 million from 4,009.99 million year-on-year, mainly due to a reduction in government subsidies and receivables[18] - Cash recovered from investments decreased by 80.70% to 17,238.22 million from 89,324.68 million year-on-year, mainly due to a reduction in financial activities[18] - Cash paid for investments dropped by 81.15% to 14,117.54 million from 74,876.95 million year-on-year, primarily due to a decrease in financial activities[18] - Cash and cash equivalents at the end of the period totaled CNY 142,300,615.44, down from CNY 401,057,700.44 at the end of the previous period[47] Operating Costs and Expenses - Total operating revenue for the period reached ¥2,442,251,280.10, an increase of 21.4% compared to ¥2,012,137,366.06 in the previous period[37] - Total operating costs amounted to ¥2,272,595,325.08, up 21.2% from ¥1,874,616,244.27 in the prior period[37] - Research and development expenses were ¥33,597,188.39, compared to ¥29,903,811.96 in the previous period, reflecting an increase of 12.4%[37] - The company experienced a 53.85% increase in taxes and surcharges, totaling ¥973.12 million, attributed to business scale growth[14] - The company reported a tax expense of CNY 38,916,227.04, which is significantly higher than CNY 21,182,699.07 in the previous period, indicating an increase of 83.5%[40] Investment Activities - The company reported a non-recurring gain from the disposal of non-current assets amounting to ¥3,620,648.56 for the quarter[8] - Long-term equity investments increased to 172,203.73 million from 132,973.35 million year-to-date, reflecting growth in the company's investment portfolio[31] - Cash paid for debt repayment increased by 56.99% to 46,168.97 million from 29,408.96 million year-on-year, primarily due to an increase in loan repayments[18] - Cash paid for other financing activities rose by 262.62% to 3,010.38 million from 830.17 million year-on-year, mainly due to an increase in the guarantee deposits for acceptance bills[18] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[39]

Financial Performance - The company reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[19]. - The gross profit margin for the first half of 2022 was 30%, compared to 28% in the same period last year[19]. - The company's operating revenue for the reporting period was ¥1,589,567,271.46, representing a 26.42% increase compared to ¥1,257,407,654.82 in the same period last year[24]. - Net profit attributable to shareholders was ¥68,345,269.80, up 12.62% from ¥60,688,458.76 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥66,887,412.92, reflecting a 20.38% increase from ¥55,561,263.65 in the previous year[24]. - The company aims to achieve a net profit margin of 10% for the full year 2022, up from 8% in 2021[19]. - The company reported a significant increase in financing activities, with net cash flow of ¥123,266,674.52, compared to a negative cash flow of ¥5,248,153.92 in the previous year, marking a 2,448.76% increase[50]. - The company reported a total of 1,950.00 million in foreign exchange forward contracts as of February 10, 2022, with a maturity date of September 9, 2022[66]. - The company reported a total of 22,037.11 thousand RMB in related party transaction amounts, with the largest transaction being 11,857.64 thousand RMB for purchasing pet snacks[130]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by the end of 2023[19]. - The company has actively expanded its market presence in countries such as the United States, Canada, Germany, and Australia[32]. - The company aims to become a leader in the global pet food industry, with a mission to promote the healthy and sustainable development of the pet industry in China[32]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[19]. - The company plans to enhance its market expansion efforts, focusing on new product development and technological advancements[200]. Research and Development - The company has invested RMB 50 million in R&D for new technologies aimed at improving product quality and safety standards[19]. - Research and development expenses rose by 8.50% to ¥22,845,107.43, compared to ¥21,055,361.73 in the previous year[50]. - The company holds 152 authorized patents, including 15 invention patents, and has been recognized as a national high-tech enterprise since 2012[47]. - The company emphasizes continuous R&D investment and aims to expand its product line and market presence while maintaining quality standards[45]. Financial Health and Assets - The company's total assets at the end of the reporting period were ¥3,239,132,645.80, a 7.43% increase from ¥3,015,181,615.47 at the end of the previous year[24]. - The company's cash and cash equivalents increased by 194.42% to ¥23,606,447.39, compared to a decrease of ¥25,000,972.51 in the previous year[50]. - The total liabilities of the company as of the end of the reporting period were CNY 868,330,890.49, compared to CNY 805,454,377.56 at the end of the previous year[181]. - The total owner's equity reached CNY 2,014,569,072.30, up from CNY 1,945,801,322.83, reflecting an increase of about 3.54%[175]. Risks and Challenges - The company faces industry risks including supply chain disruptions and fluctuating raw material prices, which may impact future performance[4]. - The company faces risks from trade barriers, particularly in the U.S. market, where tariffs on Chinese pet food products have increased to 25%[90]. - Rising raw material costs, particularly for chicken and duck meat, pose a risk to the company's operating margins, as price fluctuations can lead to short-term declines in gross profit margins[95]. - The ongoing COVID-19 pandemic has posed challenges to production and operations, with potential adverse effects on the company's performance if the situation does not improve[103]. Environmental and Social Responsibility - The company emphasizes the importance of environmental protection and has implemented measures to optimize product structure and improve production efficiency to achieve energy conservation and emission reduction goals[120]. - The company has a commitment to promoting the healthy and sustainable development of the pet industry while fulfilling its social responsibilities[117]. Shareholder and Governance - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company has not experienced any major litigation or arbitration matters during the reporting period[128]. - The independent directors support the company's use of financial derivatives for hedging against foreign exchange and interest rate fluctuations, which is deemed beneficial for long-term development[74].

Revenue and Profit - The company's revenue for Q1 2022 was ¥792,893,440.85, representing a 41.58% increase compared to ¥560,025,402.84 in the same period last year[6]. - Net profit attributable to shareholders was ¥23,397,267.22, up 10.73% from ¥21,129,830.61 year-on-year[6]. - The total operating revenue for the current period reached ¥792,893,440.85, a significant increase of 41.4% compared to ¥560,025,402.84 in the previous period[26]. - The net profit attributable to the parent company was ¥23,397,267.22, representing an increase of 10.7% from ¥21,129,830.61 in the previous period[28]. - The company reported a comprehensive income total of ¥29,702,794.91, compared to ¥27,463,410.90 in the prior period, reflecting a growth of 8.1%[30]. Cash Flow and Financial Activities - The net cash flow from operating activities was -¥62,788,556.39, a decrease of 204.69% compared to -¥20,607,568.48 in the previous year[6]. - Cash flow from operating activities was ¥751,754,705.13, an increase from ¥523,425,021.64 in the previous period, indicating a growth of 43.6%[31]. - The net cash flow from operating activities was -62,788,556.39 CNY, compared to -20,607,568.48 CNY in the previous period, indicating a decline in operational cash generation[33]. - Total cash outflow from investing activities was 105,293,295.94 CNY, down from 237,103,134.63 CNY, reflecting reduced investment expenditures[33]. - The net cash flow from financing activities improved to 38,367,532.69 CNY, compared to -58,673,733.06 CNY in the previous period, showing a positive shift in financing operations[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,096,606,202.33, a 2.70% increase from ¥3,015,181,615.47 at the end of the previous year[6]. - The total liabilities rose to ¥1,122,914,903.19, compared to ¥1,069,380,292.64 in the previous period, marking an increase of 5.0%[30]. - The company's total current liabilities were approximately ¥869.83 million, slightly up from ¥868.48 million, showing a marginal increase of about 0.15%[22]. - Long-term borrowings increased to approximately ¥149.64 million from ¥113.72 million, reflecting a growth of about 31.6%[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,000, with the largest shareholder holding 26.41% of the shares[13]. - The company reported a total of 77,685,750 shares held by Yantai Zhongxing Biotechnology Co., Ltd., making it the largest shareholder[18]. - The top ten shareholders collectively hold a significant portion of the company, with the largest shareholder owning approximately 24.5% of the total shares[18]. Operating Costs and Expenses - The company reported a 47.79% increase in operating costs, amounting to ¥64,653,120.00, compared to ¥43,746,500.00 in the previous year[9]. - The total operating costs amounted to ¥748,642,638.23, up 43.9% from ¥519,876,118.72 in the prior period[26]. - The company experienced a 119.41% rise in financial expenses, totaling ¥627,660.00, compared to ¥286,070.00 in the previous year[9]. - Research and development expenses increased to ¥11,768,512.49, up 23.8% from ¥9,503,858.98 in the previous period[28]. Cash and Equivalents - The company's cash and cash equivalents decreased to approximately ¥325.57 million from ¥350.86 million, a decline of about 7.2%[20]. - Cash and cash equivalents at the end of the period stood at 313,310,788.36 CNY, slightly up from 299,030,321.43 CNY[33]. Inventory and Receivables - Accounts receivable increased significantly to approximately ¥441.99 million, up from ¥345.35 million, representing a growth of about 28%[20]. - Inventory levels rose to approximately ¥533.31 million, compared to ¥516.67 million at the beginning of the year, indicating an increase of about 3.2%[20]. Other Information - The company received government subsidies amounting to ¥657,429.19 during the reporting period[8]. - The company is actively exploring new product development and market expansion strategies to enhance its competitive position in the industry[19]. - The company did not conduct an audit for the first quarter report, which may affect the reliability of the financial data presented[34].

Financial Performance - The company's revenue for Q1 2022 was CNY 560,025,402.84, representing a 41.58% increase compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 21,129,830.61, up by 10.73% year-on-year[5]. - Basic earnings per share were CNY 0.0719, reflecting a 10.71% increase from the previous year[5]. - The total operating revenue for the current period reached ¥792,893,440.85, a significant increase of 41.4% compared to ¥560,025,402.84 in the previous period[25]. - Net profit attributable to the parent company was ¥23,397,267.22, representing an increase of 10.7% from ¥21,129,830.61 in the previous period[27]. - The company’s basic and diluted earnings per share improved to ¥0.0796, up from ¥0.0719 in the previous period[29]. Cash Flow - The net cash flow from operating activities was negative at CNY -20,607,568.48, a decrease of 204.69% compared to the previous year[5]. - The company reported a net cash inflow from operating activities of ¥751,754,705.13, compared to ¥523,425,021.64 in the prior period, indicating a growth of 43.5%[30]. - The net cash flow from operating activities was -62,788,556.39, compared to -20,607,568.48 in the previous period, indicating a decline[32]. - The total cash outflow from operating activities was 814,543,261.52, compared to 544,032,590.12 in the previous period[32]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,015,181,615.47, an increase of 2.70% from the end of the previous year[5]. - The total assets of the company amounted to approximately ¥3,096,606,202.33, an increase from ¥3,015,181,615.47 at the beginning of the year[19]. - Current assets totaled ¥1,382,333,698.75, compared to ¥1,337,168,993.09 at the start of the year, reflecting a growth of about 3.4%[19]. - Total liabilities stood at ¥1,739,458,917.37, up from ¥1,737,161,422.42, showing a slight increase[21]. - The total liabilities rose to ¥1,122,914,903.19, compared to ¥1,069,380,292.64 in the previous period, indicating a growth of 5%[29]. Equity - The total equity attributable to shareholders increased by 1.44% to CNY 1,818,877,375.13[5]. - The total equity attributable to shareholders reached ¥1,845,054,764.12, an increase from ¥1,818,877,375.13, showing a growth of 1.4%[29]. Expenses - The company’s financial expenses increased by 119.41% to CNY 627.66 due to higher interest expenses[8]. - The total operating costs amounted to ¥748,642,638.23, up 43.9% from ¥519,876,118.72 in the prior period, with operating costs specifically rising from ¥437,464,995.80 to ¥646,531,239.84[25]. - Research and development expenses increased to ¥11,768,512.49, up from ¥9,503,858.98, reflecting a commitment to innovation[27]. Cash and Cash Equivalents - Cash and cash equivalents decreased to ¥325,570,848.32 from ¥350,856,030.32, a decline of approximately 7.2%[19]. - The cash and cash equivalents at the end of the period were 313,310,788.36, compared to 299,030,321.43 at the end of the previous period[32]. - The company’s initial cash and cash equivalents balance was 349,994,838.32, compared to 280,465,542.86 in the previous period[32]. Government Subsidies - The company received government subsidies amounting to CNY 657,429.19 during the reporting period[7]. Other Financial Activities - The company reported a significant decrease in cash received from investment activities, down by 72.54% to CNY 9,149.00[11]. - The total cash inflow from investment activities was 91,993,257.39, down from 334,516,021.72 in the previous period[32]. - The net cash flow from investment activities was -13,300,038.55, a significant decrease from 97,412,887.09 in the previous period[32]. - Cash inflow from financing activities totaled 175,232,021.77, compared to 84,379,318.59 in the previous period, showing an increase[32]. - The net cash flow from financing activities was 38,367,532.69, a recovery from -58,673,733.06 in the previous period[32].

Financial Performance - The company's operating revenue for 2021 was ¥2,881,552,747.12, representing a 29.06% increase compared to ¥2,232,754,482.14 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥115,615,358.39, a decrease of 14.29% from ¥134,884,756.84 in 2020[24]. - The net cash flow from operating activities increased significantly to ¥212,655,028.90, up 1,162.94% from ¥16,838,123.07 in 2020[24]. - The total assets at the end of 2021 were ¥3,015,181,615.47, a 20.47% increase from ¥2,502,840,080.12 at the end of 2020[24]. - The company reported a basic earnings per share of ¥0.39 for 2021, down 22.00% from ¥0.50 in 2020[24]. - Total revenue for 2021 reached ¥2,881,552,747.12, a 29.06% increase from ¥2,232,754,482.14 in 2020[87]. - Revenue from pet food and supplies accounted for ¥2,786,025,681.19, representing 96.68% of total revenue, with a year-on-year growth of 27.82%[87]. - Pet snacks generated ¥1,979,618,673.25 in revenue, making up 68.70% of total revenue, with a growth of 15.64% compared to the previous year[87]. - The gross profit margin for pet food and supplies was 20.60%, down 4.47% from the previous year[87]. - Revenue from overseas markets was ¥2,190,871,906.79, accounting for 76.03% of total revenue, with a year-on-year increase of 29.58%[87]. Market Overview - The pet industry in China reached a market size of 249 billion RMB in 2021, growing by 20.60% compared to 2020, with an average annual growth rate of 16.75% from 2017 to 2021[45][46]. - Pet food accounted for over 50% of total pet consumption expenditure in both 2020 and 2021, indicating its dominance in the market[45]. - The fastest-growing segment in pet consumption is pet medical services, which saw an increase of 3.40 percentage points in 2021 compared to the previous year[45]. - The pet food market in China reached a scale of 128.235 billion RMB in 2021, growing by 20.6% compared to 2020[67]. - The average annual growth rate of China's pet food market from 2017 to 2021 was 16.82%[67]. - The pet staple food market accounted for 891.72 billion RMB in 2021, increasing by 150.09 billion RMB from 2020[67]. - The pet snack market size was 346.11 billion RMB in 2021, decreasing by 21.46 billion RMB from 2020[67]. Company Strategy and Operations - The company aims to expand its market reach through strategic partnerships and acquisitions in the pet food industry[16]. - The company operates under a dual-driven strategy, focusing on both domestic and international markets[71]. - The company aims to become a leader in the global pet food industry, with a mission to promote healthy and sustainable development in the pet industry[71]. - The company has established a comprehensive product line including pet dry food, wet food, and snacks, with core brands such as "Wanpy," "Zeal," and "Toptrees" recognized in the domestic market[79]. - The company has developed a product matrix with over 1,000 varieties, including dry food, wet food, and snacks[72]. - The company plans to increase production capacity and develop new products while strengthening its domestic market presence[83]. - The company aims to enhance its product line and market share through the development of new pet food products and optimization of existing processes[102]. Research and Development - The company has a strong focus on research and development for new products and technologies in the pet food sector[16]. - The company emphasizes R&D, with a dedicated technology center and a structured project development process to ensure innovation and quality[84]. - The company has invested over RMB 10 million in a pet food testing base, recognized as one of the largest and best-equipped facilities in China[84]. - The company holds 144 national patents, including 14 invention patents, and has been recognized as a national high-tech enterprise since 2012[84]. - Research and development (R&D) expenses rose by 19.30% to ¥41,288,460.61, representing 1.43% of operating revenue[102]. Governance and Compliance - The company maintains a governance structure that complies with the requirements of the Company Law and the Securities Law, ensuring the protection of shareholder rights[161]. - The board of directors consists of 9 members, including 3 independent directors, fulfilling legal and regulatory requirements[163]. - The supervisory board is composed of 3 members, including 1 employee representative, ensuring compliance with legal and regulatory standards[164]. - The company has established independent financial, personnel, and operational systems, ensuring independence from its controlling shareholders[166]. - The company has a clear asset ownership structure, with no reliance on controlling shareholders for production operations[167]. - The company has an independent human resources department, ensuring that management decisions are made without interference from controlling shareholders[168]. Investment and Financial Management - The company reported a significant portion of its revenue from foreign sales, primarily in USD, which poses risks related to exchange rate fluctuations[130]. - The company has implemented risk management strategies for financial derivatives, including selecting simple and liquid products to hedge against exchange rate and interest rate risks[129]. - The company has a total of 33,822.56 million RMB in derivative investments, with a risk analysis indicating potential impacts from market volatility[129]. - The company has established a dedicated team to oversee derivative investments and ensure compliance with operational procedures[129]. - The company has approved a proposal for external investment and acquisition of overseas equity[200]. Future Outlook - The company projects a revenue growth of 10% for the next fiscal year, aiming for 1.32 billion RMB[185]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on premium pet food lines[185]. - The company plans to enhance its e-commerce platform, aiming for a 40% increase in online sales[185]. - Future guidance indicates a projected revenue growth rate of approximately 15% for the upcoming fiscal year, driven by new product launches and market expansion initiatives[197].

证券代码：002891 证券简称：中宠股份 公告编号：2021-089 烟台中宠食品股份有限公司 关于参加山东辖区上市公司 2021 年度 投资者网上集体接待日活动的公告 | --- | |---------------------------------------------------------------------------------------------------| | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 \n误导性陈述或重大遗漏。 | | 为进一步加强与广大投资者的沟通交流，切实提高上市公司透明度、规范运 | | 作和公司治理水平，烟台中宠食品股份有限公司（以下简称"公司"）将参加由 | | 山东证监局、山东上市公司协会与深圳市全景网络有限公司联合举办的"山东辖 | | 区上市公司 2021 年度投资者网上集体接待日"活动，现将有关事项公告如下： | | 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 | | 上平台举行，投资者可以登录全景·路演天下（ http://rs.p5w.net | | 网上互动交流时间为 2021 年 ...